ReviewJournal of hematology & oncology2011
Novel agents for anti-platelet therapy.
Review in Journal of hematology & oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 44 citations in OpenAlex.
- Polymeric anti-platelet carriers for the precision-targeting of age-related cardiovascular and cerebrovascular diseases.Materials today. Bio · 2026Review
- Statin Monotherapy Not Inferior to Aspirin or Combined Aspirin and Statins Reducing the Incidences of Cirrhosis, HCC, and Mortality in MAFLD/MASH Patients: A Population Cohort Study.International journal of general medicine · 2024Article
- Are Antisense Long Non-Coding RNA Related to COVID-19?Biomedicines · 2022Article
- Von Willebrand factor: A key glycoprotein involved in thrombo-inflammatory complications of COVID-19.Chemico-biological interactions · 2021Review
- SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19.Journal of hematology & oncology · 2020Article
- In silico identification of new inhibitors for βeta-2-glycoprotein I as a major antigen in antiphospholipid antibody syndrome.Journal of molecular modeling · 2020Article
- Engineered platelets with antithrombotic and antimetastatic properties.Stem cell investigation · 2019Article
- A Novel Pentapeptide Targeting Integrin β3-Subunit Inhibits Platelet Aggregation and Its Application in Rat for Thrombosis Prevention.Frontiers in pharmacology · 2016Article
- Lower circulating platelet counts and antiplatelet therapy independently predict better outcomes in patients with head and neck squamous cell carcinoma.Journal of hematology & oncology · 2014Article
- Three-dimensional multi-scale model of deformable platelets adhesion to vessel wall in blood flow.Philosophical transactions. Series A, Mathematical, physical, and engineering sciences · 2014Article
- Thromboelastometric and platelet responses to silk biomaterials.Scientific reports · 2014Article
- Article
- Article
- Role of Pannexin-1 hemichannels and purinergic receptors in the pathogenesis of human diseases.Frontiers in physiology · 2014Review
- cDNA cloning of a snake venom metalloproteinase from the eastern diamondback rattlesnake (Crotalus adamanteus), and the expression of its disintegrin domain with anti-platelet effects.Toxicon : official journal of the International Society on Toxinology · 2013Article
- Is There Still a Role for Glycoprotein IIb/IIIa Antagonists in Acute Coronary Syndromes?Cardiology research · 2013Review
- Synthesis and Anti-Platelet Activity of Thiosulfonate Derivatives Containing a Quinone Moiety.Scientia pharmaceuticaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anti-platelet therapy plays an important role in the treatment of patients with thrombotic diseases. The most commonly used anti-platelet drugs, namely, aspirin, ticlopidine, and clopidogrel, are effective in the prevention and treatment of cardio-cerebrovascular diseases. Glycoprotein IIb/IIIa antagonists (e.g., abciximab, eptifibatide and tirofiban) have demonstrated good clinical benefits and safety profiles in decreasing ischemic events in acute coronary syndrome. However, adverse events related to thrombosis or bleeding have been reported in cases of therapy with glycoprotein IIb/IIIa antagonists. Cilostazol is an anti-platelet agent used in the treatment of patients with peripheral ischemia, such as intermittent claudication. Presently, platelet adenosine diphosphate P2Y(12) receptor antagonists (e.g., clopidogrel, prasugrel, cangrelor, and ticagrelor) are being used in clinical settings for their pronounced protective effects. The new protease-activated receptor antagonists, vorapaxar and atopaxar, potentially decrease the risk of ischemic events without significantly increasing the rate of bleeding. Some other new anti-platelet drugs undergoing clinical trials have also been introduced. Indeed, the number of new anti-platelet drugs is increasing. Consequently, the efficacy of these anti-platelet agents in actual patients warrants scrutiny, especially in terms of the hemorrhagic risks. Hopefully, new selective platelet inhibitors with high anti-thrombotic efficiencies and low hemorrhagic side effects can be developed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.